Forte Biosciences Financials
| FBRX Stock | USD 8.17 0.63 8.36% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.04 | 9.41 |
|
|
The financial analysis of Forte Biosciences is a critical element in measuring its lifeblood. Investors should not minimize Forte Biosciences' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Forte | Select Account or Indicator |
Understanding current and past Forte Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Forte Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Forte Biosciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Forte Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Forte Biosciences. Check Forte Biosciences' Beneish M Score to see the likelihood of Forte Biosciences' management manipulating its earnings.
Forte Biosciences Stock Summary
Forte Biosciences competes with Indaptus Therapeutics, Rezolute, Tempest Therapeutics, ABVC Biopharma, and Pasithea Therapeutics. Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. Forte Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US34962G2084 |
| CUSIP | 34962G109 888846102 34962G208 |
| Location | California; U.S.A |
| Business Address | 3060 Pegasus Park |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.fortebiorx.com |
| Phone | 310 618 6994 |
| Currency | USD - US Dollar |
Forte Biosciences Key Financial Ratios
| Return On Equity | -1.37 | ||||
| EBITDA | (32.48 M) | ||||
| Net Income | (31.48 M) | ||||
| Cash Per Share | 1.89 X | ||||
| Current Ratio | 25.67 X |
Forte Biosciences Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 61.2M | 43.3M | 42.0M | 39.0M | 35.1M | 43.2M | |
| Other Current Liab | 1.0M | 812K | 2.0M | 2.2M | 2.0M | 4.0M | |
| Net Debt | (58.8M) | (42.0M) | (41.1M) | (12.0M) | (10.8M) | (11.3M) | |
| Retained Earnings | (51.5M) | (73.2M) | (87.0M) | (118.5M) | (136.3M) | (143.1M) | |
| Accounts Payable | 1.2M | 946K | 1.2M | 1.4M | 1.3M | 1.3M | |
| Cash | 58.8M | 42.0M | 41.1M | 12.0M | 13.8M | 13.1M | |
| Other Current Assets | 1.1M | 476K | 411K | 1.2M | 1.1M | 831.3K | |
| Total Liab | 2.3M | 1.8M | 3.2M | 3.7M | 3.3M | 3.1M | |
| Total Current Assets | 59.9M | 42.5M | 41.5M | 38.3M | 34.5M | 41.8M | |
| Net Tangible Assets | (4.8M) | 59.0M | 41.5M | 38.8M | 44.6M | 29.4M | |
| Net Invested Capital | 59.0M | 41.5M | 38.8M | 35.3M | 40.6M | 37.4M | |
| Capital Stock | 13K | 15K | 21K | 36K | 41.4K | 43.5K | |
| Net Working Capital | 57.6M | 40.8M | 38.3M | 34.7M | 39.9M | 38.9M |
Forte Biosciences Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Income | 1.4M | 2.3M | 162K | 1.1M | 1.3M | 1.3M | |
| Interest Expense | 3.8M | 0.0 | 222K | 17K | 15.3K | 14.5K | |
| Gross Profit | (11K) | (54K) | (36K) | (9K) | (8.1K) | (7.7K) | |
| Operating Income | 17.8M | (21.5M) | (13.9M) | (32.5M) | (37.4M) | (39.2M) | |
| Ebit | (46.5M) | (21.5M) | (13.9M) | (32.5M) | (37.4M) | (39.2M) | |
| Research Development | 10.0M | 13.9M | 5.6M | 21.9M | 19.7M | 16.1M | |
| Ebitda | (46.4M) | (21.5M) | (13.9M) | (32.5M) | (37.3M) | (39.2M) | |
| Income Before Tax | (46.5M) | (21.7M) | (13.9M) | (31.5M) | (36.2M) | (38.0M) | |
| Net Income | (78.5M) | (21.7M) | (13.9M) | (31.5M) | (36.2M) | (38.0M) | |
| Income Tax Expense | (2.5K) | 32.1M | (200.6K) | (17K) | (19.6K) | (18.6K) |
Forte Biosciences Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Forte Biosciences. It measures of how well Forte is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Forte Biosciences brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Forte had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Forte Biosciences has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 51.8M | (16.7M) | (944K) | (4.0M) | (3.6M) | (3.4M) | |
| Free Cash Flow | (18.4M) | (16.7M) | (8.2M) | (28.8M) | (33.1M) | (34.8M) | |
| Depreciation | 54K | 36K | 0.0 | 9K | 8.1K | 7.7K | |
| Other Non Cash Items | 30.9M | 61K | 3.8M | (131K) | (150.7K) | (143.1K) | |
| Capital Expenditures | 161.6K | 0.0 | 61K | 88K | 79.2K | 75.2K | |
| Net Income | (46.5M) | (21.7M) | (13.9M) | (31.5M) | (36.2M) | (38.0M) | |
| End Period Cash Flow | 58.8M | 42.0M | 41.1M | 37.1M | 42.7M | 33.3M |
Forte Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Forte Biosciences's current stock value. Our valuation model uses many indicators to compare Forte Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Forte Biosciences competition to find correlations between indicators driving Forte Biosciences's intrinsic value. More Info.Forte Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Forte Biosciences' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Forte Biosciences' earnings, one of the primary drivers of an investment's value.Forte Biosciences Systematic Risk
Forte Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Forte Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Forte Biosciences correlated with the market. If Beta is less than 0 Forte Biosciences generally moves in the opposite direction as compared to the market. If Forte Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Forte Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Forte Biosciences is generally in the same direction as the market. If Beta > 1 Forte Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Forte Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Forte Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Forte Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Forte Biosciences March 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Forte Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Forte Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Forte Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Forte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Forte Biosciences's daily price indicators and compare them against related drivers.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 28.46 | |||
| Value At Risk | (12.11) | |||
| Potential Upside | 9.14 |
Additional Tools for Forte Stock Analysis
When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.